Access Natriuretic Peptide Assay(s) Pivotal - Emergency Department Subject Enrollment and Specimen Collection
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04169815. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pivotal Evaluation of the Access Natriuretic Peptdie Assay(s) as an Aid in the Diagnosis and Assessment of Severity of Acute Heart Failure - Emergency Department Subject Enrollment and Specimen Collection
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the pivotal study is to collect blood specimens and clinical data from patients suspected of having Heart Failure (HF), which will be tested at a future date on Natriuretic Peptide assay(s) to validate diagnostic cutoffs and assess HF severity.
Study identification
- NCT ID
- NCT04169815
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 2,370 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 21 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 20, 2019 (Actual)
- Primary completion
- May 31, 2022 (Actual)
- Completion
- Sep 30, 2022 (Actual)
- Last update posted
- Feb 14, 2023
2019 – 2022
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Beckman Coulter Site AJ | Loma Linda | California | 92354 | — |
| Beckman Coulter Site AL | Sacramento | California | 95817 | — |
| Beckman Coulter Site AB | Gainesville | Florida | 32608 | — |
| Beckman Coulter Site AG | Indianapolis | Indiana | 46202 | — |
| Beckman Coulter Site AN | Kansas City | Kansas | 66160 | — |
| Beckman Coulter Site AA | Detroit | Michigan | 48202 | — |
| Beckman Coulter Site AH | St Louis | Missouri | 63110 | — |
| Beckman Coulter Site AI | Albuquerque | New Mexico | 87106 | — |
| Beckman Coulter Site AE | Stony Brook | New York | 11794 | — |
| Beckman Coulter Site AK | Cleveland | Ohio | 44109 | — |
| Beckman Coulter Site AF | Columbus | Ohio | 43210 | — |
| Oregon Health and Science University | Portland | Oregon | 97208-3003 | — |
| Beckman Coulter Site AC | Charleston | South Carolina | 29425 | — |
| Beckman Coulter Site AD | Nashville | Tennessee | 37235 | — |
| Beckman Coulter Site AM | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04169815, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 14, 2023 · Synced Nov 15, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.